Ivy Brain Tumor Center
12
5
9
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
8.3%
1 terminated/withdrawn out of 12 trials
66.7%
-19.8% vs industry average
8%
1 trials in Phase 3/4
100%
2 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
Role: lead
Abemaciclib in Newly Diagnosed Meningioma Patients
Role: collaborator
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
Role: collaborator
AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients
Role: collaborator
LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients
Role: collaborator
Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients
Role: collaborator
A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions
Role: collaborator
Infigratinib in Recurrent High-Grade Glioma Patients
Role: collaborator
A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection
Role: collaborator
Study of Sonodynamic Therapy in Participants with Recurrent High-Grade Glioma
Role: collaborator
Study of Pamiparib in Newly Diagnosed and rGBM
Role: collaborator
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
Role: collaborator
All 12 trials loaded